Dicot Pharma AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Dicot Pharma AB (KN0) - Total Liabilities
Latest total liabilities as of June 2025: €12.00 Million EUR
Based on the latest financial reports, Dicot Pharma AB (KN0) has total liabilities worth €12.00 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dicot Pharma AB - Total Liabilities Trend (2021–2024)
This chart illustrates how Dicot Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dicot Pharma AB Competitors by Total Liabilities
The table below lists competitors of Dicot Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neontech Co. Ltd
KQ:306620
|
Korea | ₩105.48 Billion |
|
Powertip Technology Corporation
TWO:6167
|
Taiwan | NT$508.68 Million |
|
Fluent Inc
NASDAQ:FLNT
|
USA | $54.47 Million |
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
USA | $1.93 Million |
|
Frontier Energy Ltd
AU:FHE
|
Australia | AU$855.45K |
|
CATES ELEKTRIK
IS:CATES
|
Turkey | TL1.14 Billion |
|
ASICLAND
KQ:445090
|
Korea | ₩96.24 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Dicot Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dicot Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dicot Pharma AB (2021–2024)
The table below shows the annual total liabilities of Dicot Pharma AB from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €11.96 Million | +30.48% |
| 2023-12-31 | €9.16 Million | +30.64% |
| 2022-12-31 | €7.01 Million | +105.01% |
| 2021-12-31 | €3.42 Million | -- |